Brief news reports on Tuberculosis

Burden of tuberculosis disease in Nigeria

Tuberculosis (TB) has emerged as the single leading cause of death from any single infectious agent and has continued to be a major public health problem all over the world.

Read More →

Janssen seeks accelerated FDA approval for bedaquiline to treat MDR-TB

If approved by the FDA, bedaquiline would be the first drug with a new mechanism of action for TB in more than 40 years and the first and only one specifically indicated for MDR-TB.

Read More →

Assay demonstrates 96 percent accuracy in detecting rifampin-resistant TB

Great Basin Corporation, a privately-held molecular diagnostics company developing sample-to-result solutions, announced today that a study published in the July issue of the Journal of Clinical Microbiology demonstrates its TB ID/R assay to be 96 percent accurate in detecting rifampin-resistant Mycobacterium tuberculosis (TB). The assay is currently under development to provide rapid diagnosis and drug susceptibility information for TB.

Read More →

Real-time multiple mutation detection technology for drug resistant mutations in TB to be introduced

Seegene Inc., a leading developer of multiplex molecular diagnostic technologies and tests, today announced that it will introduce Quantplex(TM) MTB/MDR/XDR Detection, a real time test that detects Mycobacterium tuberculosis and resistance mutations associated with multiple drug resistant (MDR) and extensively drug resistant (XDR) forms of M. tuberculosis at the 2012 American Association of Clinical Chemistry (AACC) annual meeting, held in Los Angeles, from July 17-19. This new test is based on powerful enhancements to the company's TOCE(TM) technology, called Cleavage Site Specific Extension (TOCE-CSSE), that enables high multiplex mutation detection of disease.

Read More →

AstraZeneca and Cellworks collaborate to find new treatment for tuberculosis

AstraZeneca and Cellworks today announced a collaboration supported by the Wellcome Trust to speed the design of novel combination therapies for the treatment of drug-sensitive and resistant tuberculosis. This collaboration will also pave the way for the creation of platforms and approaches to handle Multi Drug Resistant Tuberculosis (MDR-TB), a condition that is reaching epidemic proportions in many developing parts of the world.

Read More →

PWRDF begins 5-year $2 million Health Care Program

The Primate’s World Relief and Development Fund is undertaking, with the financial support of the Government of Canada provided through the Canadian International Development Agency (CIDA), a health care project in South Africa.  PWRDF will contribute half a million dollars over five years towards the $2 million project that will focus on preventing HIV/AIDS and tuberculosis among pregnant women in the Ngqushwa district of the Eastern Cape, South Africa.

Read More →

New DNA test to help in global effort to control TB

A new diagnostic DNA test has been developed by a team at the National University of Ireland Galway to help in the global effort to control tuberculosis (TB). The rapid laboratory test allows for the identification of the exact bacteria causing a patient’s TB which will give valuable information for their treatment.

Read More →

TB treatment paradox: Mouse studies show body’s own response helps TB bacteria survive

Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could — paradoxically — shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children’s Center and the Center for TB Research.

Read More →

With third-highest TB burden, South Africa is critical player in search for vaccine

The following is a guest post by  Jim Connolly,  president and CEO of Aeras, a nonprofit product development partnership dedicated to the development of tuberculosis vaccines. Aeras is located in Rockville, MD and operates an office in Cape Town, South Africa. 

Read More →

Recognizing excellence in the fight against childhood TB: Kochon Prize calls for nominations

Nominations for the 2012 Stop TB Partnership-Kochon Prize are being accepted until 1 September 2012. Funded by the Kochon Foundation, a non-profit foundation registered in the Republic of Korea, the US$ 65 000 prize is awarded once a year to persons, institutions, or organizations that have made a highly significant contribution to combating tuberculosis (TB).

Read More →

Page 486 of 557 · Total posts: 10

←First 485 486 487 Last→